Drug-buying agency Pharmac has announced that for the first time a medicine specifically targetting Alzheimer's Disease and dementia will be funded in New Zealand.
Pharmac revealed that it plans to buy the Donepezil Rex brand of medicines after the drug is registered with medicines safety regulator Medsafe. This decision was made because evidence indicates drugs belonging to the class of acetylchlorinesterase inhibitors may slow the progression of Alzheimer's in some patients.
AdvertisementDonepizil will become available without restriction to an estimated 15,000 people in the country after Pharmac managed to reduce the $32 million price tag on the drug by 95%.
You May Also Like